BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 20408342)

  • 1. Glatiramer acetate: successful desensitization for treatment of multiple sclerosis.
    Bains SN; Hsieh FH; Rensel MR; Radojicic C; Katz HT; Inamdar SR; Lang DM
    Ann Allergy Asthma Immunol; 2010 Apr; 104(4):321-5. PubMed ID: 20408342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Long-term effects of glatiramer acetate in multiple sclerosis].
    Brochet B
    Rev Neurol (Paris); 2008 Nov; 164(11):917-26. PubMed ID: 18790510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Desensitization to imatinib in patients with leukemia.
    Nelson RP; Cornetta K; Ward KE; Ramanuja S; Fausel C; Cripe LD
    Ann Allergy Asthma Immunol; 2006 Aug; 97(2):216-22. PubMed ID: 16937754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effectiveness of glatiramer acetate in clinical practice: an observational study.
    Fernández-Fernández Ó; Garcia-Trujillo L; Guerrero-Fernández M; León A; López-Madrona JC; Alonso A; Bustamante R; Fernández-Sánchez VE
    Rev Neurol; 2012 Jan; 54(1):1-9. PubMed ID: 22187206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III dose-comparison study of glatiramer acetate for multiple sclerosis.
    Comi G; Cohen JA; Arnold DL; Wynn D; Filippi M;
    Ann Neurol; 2011 Jan; 69(1):75-82. PubMed ID: 21280077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allergy workup in immediate-type local reactions to glatiramer acetate.
    Sánchez-López J; Rodríguez del Rio P; Cases-Ortega B; Martínez-Cócera C; Fernández-Rivas M
    J Investig Allergol Clin Immunol; 2010; 20(6):521-3. PubMed ID: 21243937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modified protocol for desensitization to glatiramer acetate.
    Sheth SS; Posner MA
    Ann Allergy Asthma Immunol; 2010 Aug; 105(2):190. PubMed ID: 20674837
    [No Abstract]   [Full Text] [Related]  

  • 8. Endermology: a treatment for injection-induced lipoatrophy in multiple sclerosis patients treated with sub cutaneous glatiramer acetate.
    Lebrun C; Mondot L; Bertagna M; Calleja A; Cohen M
    Clin Neurol Neurosurg; 2011 Nov; 113(9):721-4. PubMed ID: 21839580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lobular panniculitis at the site of glatiramer acetate injections for the treatment of relapsing-remitting multiple sclerosis. A report of two cases.
    Ball NJ; Cowan BJ; Moore GR; Hashimoto SA
    J Cutan Pathol; 2008 Apr; 35(4):407-10. PubMed ID: 18333902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glatiramer: new preparation. No place in multiple sclerosis.
    Prescrire Int; 2004 Feb; 13(69):10-2. PubMed ID: 15055208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological mechanisms underlying delayed-type hypersensitivity reactions to glatiramer acetate.
    Mayorga C; Blazquez AB; Doña I; Gomez F; Chaves P; Sanchez-Quintero MJ; Blanca-López N; Melendez L; Blanca M; Torres MJ
    Ann Allergy Asthma Immunol; 2012 Jul; 109(1):47-51. PubMed ID: 22727157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Localized panniculitis secondary to subcutaneous glatiramer acetate injections for the treatment of multiple sclerosis: a clinicopathologic and immunohistochemical study.
    Soares Almeida LM; Requena L; Kutzner H; Angulo J; de Sa J; Pignatelli J
    J Am Acad Dermatol; 2006 Dec; 55(6):968-74. PubMed ID: 17097393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of glatiramer acetate treatment on pre-existing headaches in patients with MS.
    Pöllmann W; Erasmus LP; Feneberg W; Straube A
    Neurology; 2006 Jan; 66(2):275-7. PubMed ID: 16434675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Link of the mechanisms of action of glatiramer acetate to its long-term clinical data.
    Moreau T
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S12-5. PubMed ID: 19200858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patients.
    Castelli-Haley J; Oleen-Burkey M; Lage MJ; Johnson KP
    Adv Ther; 2008 Jul; 25(7):658-73. PubMed ID: 18641926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lessons from randomised direct comparative trials.
    Achiron A; Fredrikson S
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S19-24. PubMed ID: 19200860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful Rapid Desensitization to Glatiramer Acetate in a Patient With Multiple Sclerosis.
    Syrigou E; Psarros P; Grapsa D; Syrigos K
    J Investig Allergol Clin Immunol; 2015; 25(3):214-5. PubMed ID: 26182688
    [No Abstract]   [Full Text] [Related]  

  • 18. Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis.
    Kornek B; Bernert G; Balassy C; Geldner J; Prayer D; Feucht M
    Neuropediatrics; 2003 Jun; 34(3):120-6. PubMed ID: 12910434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Desensitization in interferon-beta1a allergy: a case report.
    Fusun Kalpaklioglu A; Baccioglu Kavut A; Erdemoglu AK
    Int Arch Allergy Immunol; 2009; 149(2):178-80. PubMed ID: 19127077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic reaction to glatiramer acetate.
    Bayerl C; Bohland P; Jung EG
    Contact Dermatitis; 2000 Jul; 43(1):62-3. PubMed ID: 10902605
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.